<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007928/" ref="ordinalpos=1774&amp;ncbi_uid=6104213&amp;link_uid=PMC4007928" image-link="/pmc/articles/PMC4007928/figure/f1-0990007/" class="imagepopup">Figure 1. From: Targeting the phosphoinositide 3-kinase <span class="highlight" style="background-color:">pathway</span> in hematologic malignancies. </a></div><br /><div class="p4l_captionBody">Key features of the phosphoinositide 3-kinase (PI3K) signaling pathway. Upon activation, class IA and B PI3Ks initiate signaling by phosphorylating phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits AKT and 3-phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane. AKT-mediated phosphorylation can activate (arrows) or inhibit (bars) downstream proteins. PI3K signaling affects cell growth, apoptosis, cell-cycle regulation, glucose metabolism, and DNA repair. Some molecular details have been omitted from this diagram for simplicity.</div></div>